Variant Bio Launches World's First Agentic AI Genomic Drug Discovery Platform
The agentic AI platform by Variant Bio, named Inference, brings together genetic and multi-omic data with autonomous analysis capabilities, and is already powering pharmaceutical partnerships totaling over USD 200 million.
Variant Bio | 09/01/2026 | By News Bureau | 125
Variant Bio partners with Boehringer Ingelheim for Research on Kidney Disease
The multi-year collaboration with Boehringer Ingelheim will leverage Variant Bio’s AI-powered Inference platform to identify novel kidney disease drug targets, with financial terms including upfront, licence and milestone payments that could exceed USD 120 million.
Variant Bio | 08/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy